Should I buy or sell Oncolytics Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares. View ONC analyst ratings or view top-rated stocks .

What is Oncolytics Biotech's stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for Oncolytics Biotech's stock. Their ONC share price targets range from C$3.00 to C$9.00. On average, they anticipate the company's share price to reach C$6.00 in the next year. This suggests a possible upside of 319.6% from the stock's current price. View analysts price targets for ONC or view top-rated stocks among Wall Street analysts .

How have ONC shares performed in 2024?

Oncolytics Biotech's stock was trading at C$1.79 on January 1st, 2024. Since then, ONC stock has decreased by 20.1% and is now trading at C$1.43. View the best growth stocks for 2024 here .

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ONC earnings forecast .

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY) , (ONCYF) (ONCYF) , Resverlogix (RVX) , Ballard Power Systems (BLDP) , ProMetic Life Sciences (PLI) , Bombardier (BDRBF) , Birchcliff Energy (BIR) , Enbridge (ENB) and First Majestic Silver (FR) .

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:ONC

Oncolytics Biotech (ONC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ONC Stock Alerts

C$1.44

+0.01 (+0.70%)

(As of 05:22 PM ET)

Compare

Today's Range: C$1.42
▼
C$1.45
50-Day Range: C$1.24
▼
C$1.59
52-Week Range: C$1.20
▼
C$4.49

Volume: 23,577 shs
Average Volume: 79,339 shs
Market Capitalization: C$108.60 million

P/E Ratio: N/A
Dividend Yield: 0.31%
Price Target: C$6.00

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines Insider Trades

Get Oncolytics Biotech alerts:

Oncolytics Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 319.6% Upside
C$6.00 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.65 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Oncolytics Biotech has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ONC.

0.0

Dividend Strength

Dividend Yield
Oncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Oncolytics Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONC.

1.3

News and Social Media Coverage

News Sentiment
Oncolytics Biotech has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
Search Interest
Only 1 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.24% of the stock of Oncolytics Biotech is held by insiders.
Percentage Held by Institutions
Only 6.98% of the stock of Oncolytics Biotech is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oncolytics Biotech is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncolytics Biotech is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncolytics Biotech has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Oncolytics Biotech Stock (TSE:ONC)

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONC Stock News Headlines

April 11, 2024 | ca.finance.yahoo.com

Stocks in play: Oncolytics Biotech® Inc.

April 11, 2024 | finance.yahoo.com

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 10, 2024 | markets.businessinsider.com

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

March 16, 2024 | theglobeandmail.com

Closing Bell: Oncolytics Bio down on Friday (ONC)

March 11, 2024 | msn.com

Futures Retreat Sharply

March 6, 2024 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

March 6, 2024 | finanznachrichten.de

Econ Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 6, 2024 | benzinga.com

A Preview Of Oncolytics Biotech's Earnings

March 2, 2024 | morningstar.com

Oncolytics Biotech Inc ONC

February 15, 2024 | markets.businessinsider.com

Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipeline

February 15, 2024 | finance.yahoo.com

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

February 14, 2024 | theglobeandmail.com

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 7, 2024 | finanznachrichten.de

USA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024

January 31, 2024 | finance.yahoo.com

KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses

January 6, 2024 | benzinga.com

Oncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictions

December 14, 2023 | markets.businessinsider.com

JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)

December 7, 2023 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

November 9, 2023 | finance.yahoo.com

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

November 3, 2023 | benzinga.com

Oncolytics Biotech's Earnings Outlook

November 3, 2023 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights

November 3, 2023 | finanznachrichten.de

Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 3, 2023 | finance.yahoo.com

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 3, 2023 | msn.com

Oncolytics Biotech GAAP EPS of -$0.14 misses by $0.06

November 3, 2023 | finance.yahoo.com

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

October 23, 2023 | marketwatch.com

Oncolytics Shares Rise 9.3% as Data Presented From Pancreatic Cancer Study

See More Headlines

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:ONC
CUSIP: N/A
CIK: N/A
Web: www.oncolyticsbiotech.com
Phone: +1-403-6707380
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$6.00
High Stock Price Target: C$9.00
Low Stock Price Target: C$3.00
Potential Upside/Downside: +319.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-27,750,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -102.66%
Return on Assets: -55.47%

Debt

Debt-to-Equity Ratio: 1.54
Current Ratio: 9.01
Quick Ratio: 8.86

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.34 per share
Price / Cash Flow: 4.22
Book Value: C$0.37 per share
Price / Book: 3.86

Miscellaneous

Outstanding Shares: 75,420,000
Free Float: N/A
Market Cap: C$107.85 million
Optionable: Not Optionable
Beta: 1.49

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Matthew C. Coffey M.B.A.
Ph.D., President, CEO & Director
Mr. Kirk J. Look C.A.
CA, Chief Financial Officer
Dr. Thomas C. Heineman M.D.
Ph.D., Chief Medical Officer
Ms. Allison Hagerman P.Eng.
P.M.P., Vice President of Product Development
Ms. Amy Goodowitz Levin
Vice President of Clinical Operations
Jon Patton
Director of Investor Relations & Communication
Mr. John Mark Lievonen BBA
C.M., FCA, LLD, MBA, Consultant

Key Competitors

View All Competitors

ONC Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings or view top-rated stocks.
What is Oncolytics Biotech's stock price target for 2024?: 3 Wall Street analysts have issued 12 month price objectives for Oncolytics Biotech's stock. Their ONC share price targets range from C$3.00 to C$9.00. On average, they anticipate the company's share price to reach C$6.00 in the next year. This suggests a possible upside of 319.6% from the stock's current price.
View analysts price targets for ONC or view top-rated stocks among Wall Street analysts.
How have ONC shares performed in 2024?: Oncolytics Biotech's stock was trading at C$1.79 on January 1st, 2024. Since then, ONC stock has decreased by 20.1% and is now trading at C$1.43.
View the best growth stocks for 2024 here.
When is Oncolytics Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ONC earnings forecast.

How were Oncolytics Biotech's earnings last quarter?: Oncolytics Biotech Inc. (TSE:ONC) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10.
What other stocks do shareholders of Oncolytics Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).
How do I buy shares of Oncolytics Biotech?: Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:ONC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oncolytics Biotech (ONC) Stock Price, News & Analysis

Oncolytics Biotech MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

Company Ownership

Earnings and Valuation

About Oncolytics Biotech Stock (TSE:ONC)

ONC Stock Price History

ONC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ONC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™